Caption Management, LLC Immuno Gen, Inc. Call Options Transaction History

Caption Management, LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 14, 2024	BUY	$12.46 - $29.95 $4.18 Million - $10 Million	335,400 Added 1341.6%	360,400 $10.7 Million
Q3 2023 Nov 14, 2023	SELL	$14.09 - $19.87 $1.2 Million - $1.69 Million	-85,000 Reduced 77.27%	25,000 $396,000
Q2 2023 Aug 14, 2023	BUY	$3.75 - $20.05 $412,500 - $2.21 Million	110,000 New	110,000 $2.08 Million
Q1 2022 May 13, 2022	SELL	$4.26 - $7.48 $852,000 - $1.5 Million	-200,000 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$5.02 - $6.59 $489,449 - $642,525	-97,500 Reduced 32.77%	200,000 $1.13 Million
Q2 2021 Aug 16, 2021	BUY	$5.79 - $8.6 $1.2 Million - $1.78 Million	207,500 Added 230.56%	297,500 $1.96 Million
Q2 2019 Aug 13, 2019	SELL	$1.8 - $3.3 $243,000 - $445,500	-135,000 Reduced 60.0%	90,000 $195,000
Q1 2019 May 14, 2019	BUY	$2.41 - $5.91 $542,250 - $1.33 Million	225,000 New	225,000 $610,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Caption Management, LLC with notifications on news.